开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2022-12-21 看看叫啥呢来自山东省

偏重的研究方向：干细胞
经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！

81 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2018-11-28 zxn2011jida

请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。

219 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2023-11-02 ms2000001424864644 来自北京

审稿速度:3.0 | 投稿命中率:25.0
经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格

72 0

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2023-03-13 Linyan Yu 来自山东省

最近有投这个期刊的老师们，请问一下初审一般要多久啊？

73 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2022-10-25 slientwo

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。

85 0

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2022-05-05 ms7000001136469102

怎么收不到decision letter，问编辑也不回信，怎么办

108 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2021-05-12 tomsyu

Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下

136 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？

114 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

选刊时有哪些需要避免的雷区？

105 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2106904, encodeId=8a7121069042d, content=偏重的研究方向：干细胞 经验分享：哈哈，大家都不要投了，2022年最新版中科院分区该杂志已被踢出一区，指挥棒威武霸气！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b4a2455253, createdName=看看叫啥呢, createdTime=Wed Dec 21 10:37:31 CST 2022, time=2022-12-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=563739, encodeId=d8c4563e3997, content=请教EMBO reports文稿提交后多久可以收到提交成功的邮件，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLQnAMuWcgbnXHKBn6SBwjLqJ87Qb1XOtrZE5zicjIqAxkKWpiaDyjtV6f8yCDq7VH7efLTibptoxFMg/132, createdBy=ba2a2048407, createdName=zxn2011jida, createdTime=Wed Nov 28 16:43:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166320, encodeId=bc0f216632088, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：有幸中过一篇虽然IF不高但是杂志质量很不错的审稿很严格, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d566480437, createdName=ms2000001424864644, createdTime=Thu Nov 02 16:59:11 CST 2023, time=2023-11-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2119273, encodeId=f2f921192e385, content=最近有投这个期刊的老师们，请问一下初审一般要多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Mon Mar 13 22:08:52 CST 2023, time=2023-03-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2095960, encodeId=7b3e209596012, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：EMBO reports现任主编是Bernd Pulverer教授，之前是Nature cell biology的主编，杂志偏向于有conceptual advance的文章，从投稿到接收平均8个月左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Oct 25 07:07:05 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217211, encodeId=9505121e2110c, content=怎么收不到decision letter，问编辑也不回信，怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Thu May 05 23:18:57 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964782, encodeId=015b964e8253, content=Under Editorial Consideration11th May 21 Manuscript Under Peer Review28th Apr 21 Under Editorial Consideration28th Apr 21 Manuscript Received22nd Apr 21 Manuscript Submitted21st Apr 21 这是最近投稿文章状态，可以参考一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed May 12 06:26:51 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089979, encodeId=14e010899e9b6, content=我能直接投nature/science这种顶级杂志吗？它们会反馈意见吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089980, encodeId=61d71089980a2, content=选刊时有哪些需要避免的雷区？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070657, encodeId=149b10e0657ae, content=偏重的研究方向：肿瘤;干细胞 经验分享：还可以，embo j退稿的回收站，到elife 差远了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=复旦生科院呵呵, createdTime=Tue Nov 16 08:59:39 CST 2021, time=2021-11-16, status=1, ipAttribution=)]

2021-11-16 复旦生科院呵呵

偏重的研究方向：肿瘤;干细胞
经验分享：还可以，embo j退稿的回收站，到elife 差远了

229 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务